Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1310 in Selected Solid Tumors
NCT06885281Phase 2Recruiting
- Sponsor
- Zai Lab
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of zocilurtatug pelitecan in neuroendocrine carcinoma (NEC), sponsored by Zai Lab. Started May 2025; status: recruiting.
02
Drugs
zocilurtatug pelitecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06885281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885281.